Title
Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids
The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids
Phase
N/ALead Sponsor
Kochi UniversityStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Liver CancerIntervention/Treatment
leucine l-isoleucine valine ...Study Participants
56The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.
This study might demonstrate a tendency of the improvement in the cumulative tumor recurrence rate after hepatectomy for liver neoplasm in the Livact group compared to that in the Control Group. The investigators believe that BCAA seems to be a remarkable benefit for liver resection, especially on its reduction in the recurrence of liver cancer. This treatment regimen has potential to offer benefits for clinical use selectively, especially for patients with chronic liver diseases.
LIVACT contains 13.0 g of free amino acids
normal dietary
The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
Inclusion Criteria: These patients were scheduled for elective liver resection to treat hepatocellular carcinoma or adenocarcinoma of the liver. Exclusion Criteria: a body-weight loss greater than 10% during the 6 months prior to surgery, the presence of distant metastases, or serious impairment of organ function due to respiratory, renal, or heart disease.
